Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Inhibrx Biosciences (INBX) Non-Current Assets (2023 - 2025)

Inhibrx Biosciences (INBX) has disclosed Non-Current Assets for 3 consecutive years, with $13.6 million as the latest value for Q4 2025.

  • Quarterly Non-Current Assets fell 33.01% to $13.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $67.1 million through Dec 2025, up 4.22% year-over-year, with the annual reading at $13.6 million for FY2025, 33.01% down from the prior year.
  • Non-Current Assets for Q4 2025 was $13.6 million at Inhibrx Biosciences, down from $16.0 million in the prior quarter.
  • The five-year high for Non-Current Assets was $20.4 million in Q4 2024, with the low at $12.5 million in Q4 2023.
  • Average Non-Current Assets over 3 years is $16.4 million, with a median of $16.2 million recorded in 2024.
  • The sharpest move saw Non-Current Assets surged 62.5% in 2024, then crashed 33.01% in 2025.
  • Over 3 years, Non-Current Assets stood at $12.5 million in 2023, then surged by 62.5% to $20.4 million in 2024, then plummeted by 33.01% to $13.6 million in 2025.
  • According to Business Quant data, Non-Current Assets over the past three periods came in at $13.6 million, $16.0 million, and $18.2 million for Q4 2025, Q3 2025, and Q2 2025 respectively.